[1]Bak DW, Bechtel TJ, Falco JA, et al. Cysteine reactivity across the subcellular universe[J]. Curr Opin Chem Biol, 2019, 48: 96-105.
[2]Jones DP, Go YM. Mapping the cysteine proteome: analysis of redoxsensing thiols[J]. Curr Opin Chem Biol, 2011, 15(1): 103-112.
[3]Demir Pektas S, Pektas G, Tosun K, et al. Evaluation of erythroid disturbance and thioldisulphide homeostasis in patients with psoriasis[J]. Biomed Res Int, 2018, 2018: 9548252.
[4]AverillBates DA. The antioxidant glutathione[J]. Vitam Horm, 2023, 121: 109-141.
[5]Yang Y, Song Y, Loscalzo J. Regulation of the protein disulfide proteome by mitochondria in mammalian cells[J]. Proc Natl Acad Sci U S A, 2007, 104(26): 10813-10817.
[6]Nagy P. Kinetics and mechanisms of thioldisulfide exchange covering direct substitution and thiol oxidationmediated pathways[J]. Antioxid Redox Signal, 2013, 18(13): 1623-1641.
[7]Liu X, Nie L, Zhang Y, et al. Actin cytoskeleton vulnerability to disulfide stress mediates disulfidptosis[J]. Nat Cell Biol, 2023, 25(3): 404-414.
[8]Liu X, Olszewski K, Zhang Y, et al. Cystine transporter regulation of pentose phosphate pathway dependency and disulfide stress exposes a targetable metabolic vulnerability in cancer[J]. Nat Cell Biol, 2020, 22(4): 476-486.
[9]Liu X, Gan B. Glucose starvation induces NADPH collapse and disulfide stress in SLC7A11(high) cancer cells[J]. Oncotarget, 2021, 12(16): 1629-1630.
[10]Miller CG, Schmidt EE. Sulfur metabolism under stress[J]. Antioxid Redox Signal, 2020, 33(16): 1158-1173.
[11]Mistry RK, Brewer AC. Redoxdependent regulation of sulfur metabolism in biomolecules: implications for cardiovascular health[J]. Antioxid Redox Signal, 2019, 30(7): 972-991.
[12]Fra A, Yoboue ED, Sitia R. Cysteines as redox molecular switches and targets of disease[J]. Front Mol Neurosci, 2017, 10: 167.
[13]Stipanuk MH. Role of the liver in regulation of body cysteine and taurine levels: a brief review[J]. Neurochem Res, 2004, 29(1): 105-110.
[14]Stipanuk MH, Dominy Jr JE, Lee JI, et al. Mammalian cysteine metabolism: new insights into regulation of cysteine metabolism[J]. J Nutr, 2006, 136(6 Suppl): 1652S-1659S.
[15]Turell L, Radi R, Alvarez B. The thiol pool in human plasma: the central contribution of albumin to redox processes[J]. Free Radic Biol Med, 2013, 65: 244-253.
[16]Combs JA, DeNicola GM. The nonessential amino acid cysteine becomes essential for tumor proliferation and survival[J]. Cancers (Basel), 2019, 11(5): 678.
[17]Paul BD, Sbodio JI, Snyder SH. Cysteine metabolism in neuronal redox homeostasis[J]. Trends Pharmacol Sci, 2018, 39(5): 513-524.
[18]Herbig K, Chiang EP, Lee LR, et al. Cytoplasmic serine hydroxymethyltransferase mediates competition between folatedependent deoxyribonucleotide and Sadenosylmethionine biosyntheses[J]. J Biol Chem, 2002, 277(41): 38381-38389.
[19]Koppula P, Zhuang L, Gan B. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy[J]. Protein Cell, 2021, 12(8): 599-620.
[20]Nakamura E, Sato M, Yang H, et al. 4F2 (CD98) heavy chain is associated covalently with an amino acid transporter and controls intracellular trafficking and membrane topology of 4F2 heterodimer[J]. J Biol Chem, 1999, 274(5): 3009-3016.
[21]Patel KA, Bartoli KM, Fandino RA, et al. Transmembrane S1 mutations in CNGA3 from achromatopsia 2 patients cause loss of function and impaired cellular trafficking of the cone CNG channel[J]. Invest Ophthalmol Vis Sci, 2005, 46(7): 2282-2290.
[22]Wang JW, Groeneveld DJ, Cosemans G, et al. Biogenesis of WeibelPalade bodies in von Willebrand′s disease variants with impaired von Willebrand factor intrachain or interchain disulfide bond formation[J]. Haematologica, 2012, 97(6): 859-866.
[23]Seirafi M, Kozlov G, Gehring K. Parkin structure and function[J]. FEBS J, 2015, 282(11): 2076-2088.
[24]Zhao QF, Yu JT, Tan L. Snitrosylation in Alzheimer′s disease[J]. Mol Neurobiol, 2015, 51(1): 268-280.
[25]Xu X, Lai Y, Hua ZC. Apoptosis and apoptotic body: disease message and therapeutic target potentials[J]. Biosci Rep, 2019, 39(1): BSR20180992.
[26]Li J, Cao F, Yin HL, et al. Ferroptosis: past, present and future[J]. Cell Death Dis, 2020, 11(2): 88.
[27]Fang Y, Tian S, Pan Y, et al. Pyroptosis: A new frontier in cancer[J]. Biomed Pharmacother, 2020, 121: 109595.
[28]于晓雪, 沈涛. 细胞程序性坏死在动脉粥样硬化中作用的研究进展[J]. 心肺血管病杂志, 2019, 38(11): 1192-1195, 1203.
[29]刘骏达, 钟薇薇, 鲁显福, 等. 铜死亡与铜代谢相关疾病研究进展[J]. 江苏大学学报(医学版), 2022, 32(4): 318-325.
[30]Trivedi MV, Laurence JS, Siahaan TJ. The role of thiols and disulfides on protein stability[J]. Curr Protein Pept Sci, 2009, 10(6): 614-625.
[31]Herrmann JM, Riemer J. Three approaches to one problem: protein folding in the periplasm, the endoplasmic reticulum, and the intermembrane space[J]. Antioxid Redox Signal, 2014, 21(3): 438-456.
[32]Saaranen MJ, Ruddock LW. Disulfide bond formation in the cytoplasm[J]. Antioxid Redox Signal, 2013, 19(1): 46-53.
[33]Cumming RC, Andon NL, Haynes PA, et al. Protein disulfide bond formation in the cytoplasm during oxidative stress[J]. J Biol Chem, 2004, 279(21): 21749-21758.
[34]Rehder DS, Borges CR. Cysteine sulfenic acid as an intermediate in disulfide bond formation and nonenzymatic protein folding[J]. Biochemistry, 2010, 49(35): 7748-7755.
[35]Cremers CM, Jakob U. Oxidant sensing by reversible disulfide bond formation[J]. J Biol Chem, 2013, 288(37): 26489-26496.
[36]Miller CG, Holmgren A, Arnér ESJ, et al. NADPHdependent and independent disulfide reductase systems[J]. Free Radic Biol Med, 2018, 127: 248-261.
[37]Arnér ES, Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase[J]. Eur J Biochem, 2000, 267(20): 6102-6109.
[38]Uziel O, Borovok I, Schreiber R, et al. Transcriptional regulation of the Staphylococcus aureus thioredoxin and thioredoxin reductase genes in response to oxygen and disulfide stress[J]. J Bacteriol, 2004, 186(2): 326-334.
[39]He Y, Chen Y, Song W, et al. A Pap1Oxs1 signaling pathway for disulfide stress in Schizosaccharomyces pombe[J]. Nucleic Acids Res, 2017, 45(1): 106-114.
[40]Zheng P, Zhou C, Ding Y, et al. Disulfidptosis: a new target for metabolic cancer therapy[J]. J Exp Clin Cancer Res, 2023, 42(1): 103.
[41]Koppula P, Zhang Y, Zhuang L, et al. Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer[J]. Cancer Commun (Lond), 2018, 38(1): 12.
[42]Chio IIC, Tuveson DA. ROS in cancer: The burning question[J]. Trends Mol Med, 2017, 23(5): 411-429.
[43]Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an irondependent form of nonapoptotic cell death[J]. Cell, 2012, 149(5): 1060-1072.
[44]Jiang L, Kon N, Li T, et al. Ferroptosis as a p53mediated activity during tumour suppression[J]. Nature, 2015, 520(7545): 57-62.
[45]Zhang Y, Shi J, Liu X, et al. BAP1 links metabolic regulation of ferroptosis to tumour suppression[J]. Nat Cell Biol, 2018, 20(10): 1181-1192.
[46]Eagle H. Nutrition needs of mammalian cells in tissue culture[J]. Science, 1955, 122(3168): 501-514.
[47]Bridges RJ, Natale NR, Patel SA. System xc- cystine/glutamate antiporter: an update on molecular pharmacology and roles within the CNS[J]. Br J Pharmacol, 2012, 165(1): 20-34.
[48]Koppula P, Zhang Y, Shi J, et al. The glutamate/cystine antiporter SLC7A11/xCT enhances cancer cell dependency on glucose by exporting glutamate[J]. J Biol Chem, 2017, 292(34): 14240-14249.
[49]Shin CS, Mishra P, Watrous JD, et al. The glutamate/cystine xCT antiporter antagonizes glutamine metabolism and reduces nutrient flexibility[J]. Nat Commun, 2017, 8: 15074.
[50]Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism[J]. Cell Metab, 2016, 23(1): 27-47.
[51]Hensley CT, Wasti AT, DeBerardinis RJ. Glutamine and cancer: cell biology, physiology, and clinical opportunities[J]. J Clin Invest, 2013, 123(9): 3678-3684.
[52]Timmerman LA, Holton T, Yuneva M, et al. Glutamine sensitivity analysis identifies the xCT antiporter as a common triplenegative breast tumor therapeutic target[J]. Cancer Cell, 2013, 24(4): 450-465.
[53]Goji T, Takahara K, Negishi M, et al. Cystine uptake through the cystine/glutamate antiporter xCT triggers glioblastoma cell death under glucose deprivation[J]. J Biol Chem, 2017, 292(48): 19721-19732.
[54]Xu F, Guan Y, Xue L, et al. The roles of ferroptosis regulatory gene SLC7A11 in renal cell carcinoma: A multiomics study[J]. Cancer Med, 2021, 10(24): 9078-9096.
[55]Ji X, Qian J, Rahman SMJ, et al. xCT (SLC7A11)mediated metabolic reprogramming promotes nonsmall cell lung cancer progression[J]. Oncogene, 2018, 37(36): 5007-5019.
[56]Zhang L, Huang Y, Ling J, et al. Overexpression of SLC7A11: a novel oncogene and an indicator of unfavorable prognosis for liver carcinoma[J]. Future Oncol, 2018, 14(10): 927-936.
[57]Badgley MA, Kremer DM, Maurer HC, et al. Cysteine depletion induces pancreatic tumor ferroptosis in mice[J]. Science, 2020, 368(6486): 85-89.
[58]Sato H, Shiiya A, Kimata M, et al. Redox imbalance in cystine/glutamate transporterdeficient mice[J]. J Biol Chem, 2005, 280(45): 37423-37429.
[59]Feng H, Stockwell BR. Unsolved mysteries: How does lipid peroxidation cause ferroptosis?[J]. PLoS Biol, 2018, 16(5): e2006203.
[60]Hu K, Li K, Lv J, et al. Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRASmutant lung adenocarcinoma[J]. J Clin Invest, 2020, 130(4): 1752-1766.
[61]Zhang Y, Tan H, Daniels JD, et al. Imidazole ketone erastin induces ferroptosis and slows tumor growth in a mouse lymphoma model[J]. Cell Chem Biol, 2019, 26(5): 623-633.e9.
[62]Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma[J]. Nature, 2014, 511(7511): 543-550.
[63]Romero R, Sayin VI, Davidson SM, et al. Keap1 loss promotes Krasdriven lung cancer and results in dependence on glutaminolysis[J]. Nat Med, 2017, 23(11): 1362-1368.
[64]GalanCobo A, Sitthideatphaiboon P, Qu X, et al. LKB1 and KEAP1/NRF2 pathways cooperatively promote metabolic reprogramming with enhanced glutamine dependence in KRASmutant lung adenocarcinoma[J]. Cancer Res, 2019, 79(13): 3251-3267.
[65]Ogiwara H, Takahashi K, Sasaki M, et al. Targeting the vulnerability of glutathione metabolism in ARID1Adeficient cancers[J]. Cancer Cell, 2019, 35(2): 177-190.e8.
[66]Liu DS, Duong CP, Haupt S, et al. Inhibiting the system x-C/glutathione axis selectively targets cancers with mutantp53 accumulation[J]. Nat Commun, 2017, 8: 14844.
|